SAN FRANCISCO, July 31, 2026 /PRNewswire/ -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ:ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company's financial condition, revenue recognition, invento…
Jerrold V. Grossman, ADMA Biologics co-founder and Vice Chairman, signed annual reports that allegedly concealed channel stuffing and an undisclosed related party distributor operating from ADMA's own headquarters.NEW YORK, July 30, 2026 /PRNewswire/ -- SueWallSt notifies investors that Jerrold V…
ADMA Biologics projected 20% ASCENIV revenue growth in 2025, but a short-seller report alleges the real figure was a 3% decline, with the gap driven entirely by an alleged channel stuffing scheme.NEW YORK, July 23, 2026 /PRNewswire/ -- SueWallSt highlights the contrast between ADMA Biologics, Inc.'…
Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026. ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, an…
ADMA Biologics, Inc.’s ADMA shares have gained 13.5% in a month compared with the industry’s growth of 8.2%.The recovery will relieve anxious investors as the stock had taken a massive beating since March-end.ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies a…
A securities fraud class action lawsuit has been filed on behalf of ADMA Biologics investors after its stock plummeted 29% due to Culper Research channel stuffing claims, potentially violating federal securities laws.NEW YORK, July 7, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti…
